Pre-clinical studies have shown that blocking podoplanin decreased thrombosis onset in cancer models, thus demonstrating that targeting podoplanin in cancer patients may be a feasible strategy in reducing thrombosis [37,38,39]. The gene discussed is PDPN; the disease is cancer.